Enhanced efficacy CAR T-cell therapies
DE602016095621T2Active Publication Date: 2026-06-17NOVARTIS AG +1
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- DE602016095621
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2015-09-17
- Filing Date
- 2016-09-16
- Publication Date
- 2026-06-17
- Estimated Expiration
- 2036-09-16
AI Technical Summary
Technical Problem
Existing CAR T cell therapies lack efficacy in treating hematologic cancers and other diseases associated with tumor antigens.
Method used
Engineering T cells to express a chimeric antigen receptor (CAR) with inhibitors of Tet1, Tet2, and/or Tet3, such as siRNA, shRNA, or gene editing systems, to disrupt these genes and reduce their expression or function, thereby enhancing CAR T cell proliferation and function.
Benefits of technology
The disruption of Tet1, Tet2, and/or Tet3 leads to decreased 5-hydroxymethylcytosine levels, improving CAR T cell proliferation and cytokine production, resulting in enhanced therapeutic efficacy against tumor antigens.
✦ Generated by Eureka AI based on patent content.
Need to check novelty before this filing date? Find Prior Art
No text content released.